» Articles » PMID: 29472722

Chromothripsis in Acute Myeloid Leukemia: Biological Features and Impact on Survival

Abstract

Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in multiple fragments and consequent random rejoining and repair. This study defines incidence of chromothripsis in 395 newly diagnosed adult acute myeloid leukemia (AML) patients from three institutions, its impact on survival and its genomic background. SNP 6.0 or CytoscanHD Array (Affymetrix) were performed on all samples. We detected chromothripsis with a custom algorithm in 26/395 patients. Patients harboring chromothripsis had higher age (p = 0.002), ELN high risk (HR) (p < 0.001), lower white blood cell (WBC) count (p = 0.040), TP53 loss, and/or mutations (p < 0.001) while FLT3 (p = 0.025), and NPM1 (p = 0.032) mutations were mutually exclusive with chromothripsis. Chromothripsis-positive patients showed a worse overall survival (OS) (p < 0.001) compared with HR patients (p = 0.011) and a poor prognosis in a COX-HR optimal regression model. Chromothripsis presented the hallmarks of chromosome instability [i.e., TP53 alteration, 5q deletion, higher mean of copy number alteration (CNA), complex karyotype, alterations in DNA repair, and cell cycle] and focal deletions on chromosomes 4, 7, 12, 16, and 17. CBA. FISH showed that chromothripsis is associated with marker, derivative, and ring chromosomes. In conclusion, chromothripsis frequently occurs in AML (6.6%) and influences patient prognosis and disease biology.

Citing Articles

Multi-omic and single-cell profiling of chromothriptic medulloblastoma reveals genomic and transcriptomic consequences of genome instability.

Smirnov P, Przybilla M, Simovic-Lorenz M, Parra R, Susak H, Ratnaparkhe M Nat Commun. 2024; 15(1):10183.

PMID: 39580568 PMC: 11585558. DOI: 10.1038/s41467-024-54547-w.


Novel insights and therapeutic approaches in secondary AML.

Marconi G, Rondoni M, Zannetti B, Zacheo I, Nappi D, Mattei A Front Oncol. 2024; 14:1400461.

PMID: 39135995 PMC: 11317385. DOI: 10.3389/fonc.2024.1400461.


Chromothripsis is a novel biomarker for prognosis and differentiation diagnosis of pancreatic neuroendocrine neoplasms.

Zhang M, He D, Zhang Y, Cheng K, Li H, Zhou Y MedComm (2020). 2024; 5(7):e623.

PMID: 38988495 PMC: 11234462. DOI: 10.1002/mco2.623.


The anti-tumor effect of trifluridine via induction of aberrant mitosis is unaffected by mutations modulating p53 activity.

Wakasa T, Nonaka K, Harada A, Ohkawa Y, Kikutake C, Suyama M Cell Death Discov. 2024; 10(1):307.

PMID: 38956056 PMC: 11219725. DOI: 10.1038/s41420-024-02083-3.


Chromothripsis in myeloid malignancies.

Chen C Ann Hematol. 2024; 103(10):3955-3962.

PMID: 38814446 PMC: 11512916. DOI: 10.1007/s00277-024-05814-9.


References
1.
Magrangeas F, Avet-Loiseau H, Munshi N, Minvielle S . Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood. 2011; 118(3):675-8. PMC: 3142904. DOI: 10.1182/blood-2011-03-344069. View

2.
Poot M, Haaf T . Mechanisms of Origin, Phenotypic Effects and Diagnostic Implications of Complex Chromosome Rearrangements. Mol Syndromol. 2016; 6(3):110-34. PMC: 4698629. DOI: 10.1159/000438812. View

3.
Govind S, Zia A, Hennings-Yeomans P, Watson J, Fraser M, Anghel C . ShatterProof: operational detection and quantification of chromothripsis. BMC Bioinformatics. 2014; 15:78. PMC: 3999944. DOI: 10.1186/1471-2105-15-78. View

4.
Liu G, Stevens J, Horne S, Abdallah B, Ye K, Bremer S . Genome chaos: survival strategy during crisis. Cell Cycle. 2013; 13(4):528-37. PMC: 6093293. DOI: 10.4161/cc.27378. View

5.
Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View